CRIS Current Research Information System

LONETTI, ANNALISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.781
NA - Nord America 9.069
EU - Europa 7.316
AF - Africa 585
SA - Sud America 518
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 5
Totale 27.293
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.938
SG - Singapore 2.702
CN - Cina 2.677
VN - Vietnam 2.428
GB - Regno Unito 2.166
SE - Svezia 1.256
DE - Germania 912
IT - Italia 848
IN - India 528
HK - Hong Kong 510
FR - Francia 463
RU - Federazione Russa 370
BR - Brasile 363
IE - Irlanda 226
ZA - Sudafrica 208
KR - Corea 197
NL - Olanda 177
UA - Ucraina 144
EE - Estonia 137
JP - Giappone 131
FI - Finlandia 129
GR - Grecia 129
TG - Togo 129
CH - Svizzera 105
CA - Canada 83
IR - Iran 71
JO - Giordania 71
NG - Nigeria 69
CI - Costa d'Avorio 68
AR - Argentina 63
PH - Filippine 59
BD - Bangladesh 58
BG - Bulgaria 57
ID - Indonesia 48
TR - Turchia 46
SC - Seychelles 42
BE - Belgio 40
PL - Polonia 37
IQ - Iraq 36
TH - Thailandia 34
PK - Pakistan 30
AT - Austria 29
MX - Messico 27
ES - Italia 26
TW - Taiwan 22
UZ - Uzbekistan 22
SA - Arabia Saudita 21
MY - Malesia 20
CO - Colombia 19
EC - Ecuador 19
AU - Australia 16
PE - Perù 14
CZ - Repubblica Ceca 13
EG - Egitto 13
CL - Cile 11
LB - Libano 10
PY - Paraguay 10
TN - Tunisia 10
DZ - Algeria 9
MA - Marocco 9
HR - Croazia 8
NP - Nepal 8
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
KE - Kenya 7
KZ - Kazakistan 7
PT - Portogallo 7
RO - Romania 7
TM - Turkmenistan 7
MU - Mauritius 6
UY - Uruguay 6
ET - Etiopia 5
OM - Oman 5
SK - Slovacchia (Repubblica Slovacca) 5
AZ - Azerbaigian 4
BB - Barbados 4
IL - Israele 4
SI - Slovenia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
KG - Kirghizistan 3
KH - Cambogia 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
RS - Serbia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
CY - Cipro 2
GY - Guiana 2
HN - Honduras 2
LT - Lituania 2
LV - Lettonia 2
MD - Moldavia 2
NI - Nicaragua 2
NO - Norvegia 2
PA - Panama 2
PS - Palestinian Territory 2
SY - Repubblica araba siriana 2
Totale 27.268
Salva come PNG Salva come JPEG
Città #
Southend 1.987
Singapore 1.928
Ashburn 857
Chandler 744
Fairfield 734
Dong Ket 625
Houston 521
San Jose 506
Hong Kong 490
Hefei 467
Wilmington 408
Ho Chi Minh City 387
Beijing 363
Woodbridge 354
Princeton 349
Ann Arbor 343
Seattle 322
Hanoi 321
Santa Clara 314
Boardman 227
Cambridge 226
Dublin 226
Nanjing 196
Lauterbourg 187
Westminster 182
Bologna 181
Padova 155
Seoul 152
Lomé 129
New York 126
Los Angeles 124
Medford 122
Helsinki 113
Redmond 101
Shenyang 94
Bern 93
Jinan 91
Dallas 88
Tokyo 87
Berlin 85
Frankfurt am Main 82
Saint Petersburg 79
Amman 69
Abidjan 68
Hebei 67
Milan 66
Redondo Beach 65
Changsha 61
Buffalo 58
Da Nang 58
Guangzhou 56
Tianjin 55
Sofia 54
Haiphong 53
Falls Church 52
Nanchang 52
Florence 49
Bremen 47
Munich 47
Shanghai 47
São Paulo 46
Bengaluru 44
Council Bluffs 44
San Diego 44
Jacksonville 43
Zhengzhou 40
Brussels 39
Turin 39
Abeokuta 35
Hangzhou 35
Norwalk 32
Ningbo 31
Jiaxing 30
Johannesburg 30
Mülheim 29
Orem 29
London 28
Toronto 28
Amsterdam 27
Redwood City 26
Taiyuan 26
Chicago 25
Haikou 25
Athens 24
Grafing 23
Jakarta 23
Hải Dương 22
Warsaw 22
Kunming 20
Xi'an 20
Bangkok 19
Istanbul 19
Rome 19
The Dalles 19
Tongling 19
Biên Hòa 18
North York 18
Phoenix 18
San Francisco 18
Can Tho 17
Totale 17.303
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 349
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 335
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 315
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 313
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 304
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 304
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 272
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 262
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. 258
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 255
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 244
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 242
COMBINING DOT1L INHIBITOR EPZ-5676 WITH SORAFENIB TO TREAT MLL-REARRANGED (MLL-R) PEDIATRIC ACUTE MYELOID LEUKEAMIA (AML) 237
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene 231
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 227
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 227
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 226
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 223
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 222
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia 221
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 219
Therapeutic targeting of CK2 in acute and chronic leukemias. 219
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 219
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 214
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 213
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 213
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 212
Improving nelarabine efficacy in T-cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. 211
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 208
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 204
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. 204
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 203
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 201
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 200
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 199
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. 199
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 199
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 198
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 197
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 196
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. 194
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 194
Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. 191
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 190
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 189
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 189
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 187
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 186
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 182
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 180
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. 179
COMBINAZIONE DI EPZ-5676 E SORAFENIB COME NUOVA STRATEGIA TERAPEUTICA PER IL TRATTAMENTO DELLE LEUCEMIE ACUTE MIELOIDI PEDIATRICHE 178
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 177
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 176
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 175
EFFICACY AND FEASIBILITY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): A SINGLE-CENTER EXPERIENCE 175
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 174
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. 172
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 171
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 171
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the pro-apoptotic NF-κB. 170
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 169
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 168
Therapeutic targeting of polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblstic leukemia. 165
Use of deep whole transcriptome sequencing in Philadelphia-positive acute lymphoblastic leukemia (ALL) to identify novel mutated genes and aberrant gene expression and alternative splicing profiles associated with disease progression. 164
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 164
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 162
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 162
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 161
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 160
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 160
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 159
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia 158
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 156
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 154
NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING TECHNOLOGY REVEALS NOVEL COMMON GENETIC ALTERATIONS IN THE HEDGEHOG PATHWAY IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 154
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 154
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 153
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 151
Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients 151
A novel DAG-dependent mechanism links PKCɑ and Cyclin B1 regulating cell cycle progression 150
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET 150
Successes and Challenges for Diagnosis and Therapy of Acute Leukemia 150
Insights on the Interplay between Cells Metabolism and Signaling: A Therapeutic Perspective in Pediatric Acute Leukemias 149
Single nucleotide polymorphisms as genomic markers for high-throughput pharmacogenomic studies 148
LOSS OF CDKN2A GENE IS A POOR PROGNOSTIC MARKER IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS 147
MULTIPLEX PCR TO RAPIDLY IDENTIFY IKZF1 (IKAROS) GENE BREAKPOINTS IN BCRABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 147
High-resolution genomic profiling of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients identified novel recurrent copy number variations involved in both pathogenesis and resistance to tyrosine kinase inhibitors 146
Inhibition of methyltransferase dot1l sensitizes to sorafenib treatment aml cells irrespective of mll-rearrangements: A novel therapeutic strategy for pediatric aml 146
New advances in targeting aberrant signaling pathways in T-cell Acute Lymphoblastic Leukemia. 145
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. 145
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 143
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 140
Improving nelarabine efficacy in refractory/relapsed T-cell Acute Lymphoblastic Leukemia by targeting aberrant PI3K/mTOR signaling 140
Genome wide analysis of Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) reveals a recurring deletion of VPREB1 gene which affects B-cell differentiation 140
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 140
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients 139
Targeting Hedgehog pathway in pediatric acute myeloid leukemia: challenges and opportunities 139
Totale 19.392
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.400
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.400
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.151 0 0 0 0 0 0 0 0 0 0 107 1.044
2021/20223.696 497 78 265 302 364 242 71 221 177 314 566 599
2022/20233.343 407 576 191 443 217 249 117 167 488 57 259 172
2023/2024843 41 146 45 66 48 185 40 44 42 44 73 69
2024/20253.270 146 487 285 229 547 175 222 94 33 234 170 648
2025/20268.237 635 828 740 590 928 521 940 443 1.728 755 129 0
Totale 27.823